Publication:
Tight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Loading...
Thumbnail Image
Date
Authors
Authors
Panaccione, Remo
Colombel, Jean-Frederic
Travis, Simon P. L.
Bossuyt, Peter
Baert, Filip
Vanasek, Tomas
Danalioglu, Ahmet
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue

Metrics

Search on Google Scholar

Abstract
Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn-s disease (CD) naive to immunosuppressants and biologics using a UK public payer perspective.
Description
Keywords
Crohn-s disease
Citation
Panaccione R., Colombel J., Travis S. P. L. , Bossuyt P., Baert F., Vanasek T., Danalioglu A., Novacek G., Armuzzi A., Reinisch W., et al., -Tight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial-, GUT, cilt.69, ss.658-664, 2020
Page Views

0

File Downloads

7

Sustainable Development Goals